Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
First received: August 10, 2001
Last updated: February 18, 2011
Last verified: October 2004

RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer.

PURPOSE: Randomized phase I trial to determine the effectiveness of celecoxib given before surgery to remove the prostate in treating patients who have localized prostate cancer.

Condition Intervention Phase
Prostate Cancer
Drug: celecoxib
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Randomized, Placebo-Controlled Trial Of Celecoxib In Men Pre-Prostatectomy For Clinically Localized Adenocarcinoma Of The Prostate: Evaluation Of Drug-Specific Biomarker Modulation

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: September 2001
Detailed Description:


  • Compare biomarker modulation (prostaglandin levels) in tissue samples of patients with localized prostate cancer treated with neoadjuvant celecoxib vs placebo followed by prostatectomy.
  • Compare the effect of these regimens on angiogenic factors within the prostate in these patients.
  • Determine the pharmacokinetic and pharmacodynamic effects of celecoxib in these patients.
  • Compare the toxicity profiles of these regimens in these patients.
  • Compare the compliance of patients treated with these regimens.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral neoadjuvant celecoxib twice daily.
  • Arm II: Patients receive oral neoadjuvant placebo twice daily. Treatment in both arms continues for at least 4 weeks followed by prostatectomy.

Patients are followed within 1 month and then at 3 months.

PROJECTED ACCRUAL: A total of 60-70 patients (at least 30 per arm) will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed localized adenocarcinoma of the prostate with one or more of the following:

    • Gleason sum at least 7
    • Prostate-specific antigen (PSA) at least 15 ng/mL
    • Clinical stage T2b or T2c (stage II)
    • Any combination of PSA, clinical stage, or Gleason sum with an estimated risk of capsular penetration greater than 45%
  • At least 3 positive core biopsies
  • Planned radical prostatectomy
  • No metastatic disease secondary to prostate cancer



  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • Not specified


  • WBC greater than 3,000/mm^3
  • Platelet count greater than 100,000/mm^3
  • Hemoglobin greater than 9 g/dL
  • No history of bleeding disorders


  • Bilirubin less than 1.5 mg/dL
  • AST/ALT less than 1.5 times upper limit of normal
  • No viral hepatitis


  • Creatinine no greater than 1.5 mg/dL OR
  • Creatinine clearance at least 50 mL/min


  • No history of hypersensitivity and/or adverse reactions to salicylates
  • No allergy to sulfa-containing medications
  • No other active malignancy within the past 5 years except superficial bladder cancer or nonmelanoma skin cancer
  • No medical or psychiatric problem that would preclude study participation
  • No active infection
  • HIV negative


Biologic therapy:

  • No prior immunologic therapy for prostate cancer


  • At least 4 weeks since prior chemotherapy and recovered

Endocrine therapy:

  • No prior androgen ablation for prostate cancer
  • At least 4 weeks since prior hormonal therapy and recovered
  • At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of glucocorticoids
  • No concurrent glucocorticoids


  • At least 4 weeks since prior radiotherapy to the pelvis or surrounding tissues and recovered


  • See Disease Characteristics
  • At least 4 weeks since prior major surgery and recovered


  • No prior investigational therapy for prostate cancer
  • No prior or concurrent chronic anticoagulants
  • No prior cyclo-oxygenase-2 inhibitor therapy (e.g., rofecoxib or celecoxib)
  • At least 4 weeks since prior initiation of vitamins (except multivitamin) or herbs with known effects on prostate function (PSA)
  • At least 30 days since prior chronic use (more than 3 times per week for more than 2 weeks) of aspirin (greater than 100 mg/day) or non-steroidal anti-inflammatory drugs (NSAIDs)
  • At least 24 hours since prior use and no concurrent use of any of the following:

    • Over-the-counter (OTC) or prescription products containing aspirin or NSAIDs; OTC products containing bismuth subsalicylate, sodium salicylate, and/or magnesium salicylate; choline salicylate; ranitidine; cimetidine; famotidine; or lansoprazole
  • No aspirin (100 mg/day) within 1 week prior to surgery
  • No concurrent addition of vitamins or herbal supplements
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00022399

United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
Study Chair: Michael A. Carducci, MD Sidney Kimmel Comprehensive Cancer Center
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00022399     History of Changes
Other Study ID Numbers: CDR0000068812, JHOC-J0007, JHOC-00030801, NCI-N01-95129, NCI-P01-0186
Study First Received: August 10, 2001
Last Updated: February 18, 2011
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I prostate cancer
stage IIB prostate cancer
stage IIA prostate cancer
adenocarcinoma of the prostate

Additional relevant MeSH terms:
Prostatic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Therapeutic Uses
Central Nervous System Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on April 23, 2014